Skip to content
Eisai
-
Eisai licenses preclinical oncology programmes to CORE Biomedicine
Under the agreement, CORE Biomedicine will evaluate and develop the licensed programmes with the aim of creating targeted treatments for a wider range of cancer patients.
-
Eisai announces US$64.5M manufacturing expansion at Hatfield hub with UK Government LSIMF grant support
The Hatfield facility, located north of London, will undergo a phased upgrade that will significantly expand its manufacturing, packaging and distribution capabilities.
-
Eisai & MSD submit the LENVIMA + WELIREG combination for RCC in Japan
In Japan alone, 21,000 new cases and 7,000 deaths were reported that year, with metastatic renal cell carcinoma (RCC) accounting for approximately 85% of all kidney cancers.
-
Eisai secures USD388M deal for Chinese cancer drug Hetronifly in Japan
Hetronifly is an anti-programmed cell death protein 1 (PD-1) monoclonal antibody that has already received regulatory approval in China for treating several solid tumor types.